CDNA CareDx
- 11.060
- +0.880+8.64%
- 12.060
- +1.000+9.04%
CareDx News
CareDx, Inc. (CDNA) Q1 2024 Earnings Call Transcript
CareDx, Inc. (CDNA) Q1 2024 Earnings Call Transcript
CareDx (CDNA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
CareDX Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Issued FY24 Revenue Guidance Above Estimates.
CareDX Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Issued FY24 Revenue Guidance Above Estimates.
CareDx Sees FY24 Revenue $274M-$282M Vs $266.955M Est.
CareDx Sees FY24 Revenue $274M-$282M Vs $266.955M Est.
CareDx Q1 2024 Adj EPS $(0.03) Beats $(0.21) Estimate, Sales $72.049M Beat $63.140M Estimate
CareDx (NASDAQ:CDNA) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.21) by 85.71 percent. This is a 72.73 percent increase over losses of $(0.11) per s
CareDx | 10-Q: Quarterly report
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersSensus Healthcare (NASDAQ:SRTS) shares increased by 33.3% to $5.08 during Thursday's after-market session. The market value of their outstanding shares is at $83.2 million. As per the news, the
Earnings Flash (CDNA) CAREDX Reports Q1 Revenue $72M, Vs. Street Est of $63.1M
04:28 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (CDNA) CAREDX Reports Q1 Revenue $72M, vs. Street Est of $63.1M
Press Release: CareDx Reports First Quarter 2024 Results
CareDx Reports First Quarter 2024 Results Raises 2024 Revenue Guidance to $274 to $282 Million BRISBANE, Calif.--(BUSINESS WIRE)--May 09, 2024-- CareDx, Inc. (Nasdaq: CDNA) -- today reported financ
CareDx 1Q Loss/Shr 32c >CDNA
CareDx 1Q Loss/Shr 32c >CDNA
CareDx Price Target Maintained With a $15.00/Share by Craig-Hallum
CareDx Price Target Maintained With a $15.00/Share by Craig-Hallum
Craig-Hallum: Reiterates CaredX (CDNA.US) rating, adjusted from buy to buy rating, target price $15.00.
Craig-Hallum: Reiterates CaredX (CDNA.US) rating, adjusted from buy to buy rating, target price $15.00.
Craig-Hallum Reiterates Buy on CareDx, Maintains $15 Price Target
Craig-Hallum analyst Connor Chamberlain reiterates CareDx (NASDAQ:CDNA) with a Buy and maintains $15 price target.
Craig-Hallum Sticks to Its Buy Rating for CareDx (CDNA)
CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare
CareDx Raised to Buy From Hold by Craig-Hallum
CareDx Raised to Buy From Hold by Craig-Hallum
CareDx Price Target Raised to $15.00/Share From $12.00 by Craig-Hallum
CareDx Price Target Raised to $15.00/Share From $12.00 by Craig-Hallum
Craig-Hallum: Raised the CaredX (CDNA.US) rating from holding to buying, and adjusted the target price from $12.00 to $15.00.
Craig-Hallum: Raised the CaredX (CDNA.US) rating from holding to buying, and adjusted the target price from $12.00 to $15.00.
Craig-Hallum Upgrades CareDx to Buy, Raises Price Target to $15
Craig-Hallum analyst Alexander Nowak upgrades CareDx (NASDAQ:CDNA) from Hold to Buy and raises the price target from $12 to $15.
Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD) fell sharply during Wednesday's session as the company reported first-quarter results and issued revenue guidance for the second quarter.AMD guided
Analysis
Price Target
No Data
